Branded drug products have fewer potential cost-saving limits on them in Medicare Part D formularies, researchers at John Hopkins University have found.
Branded drug products have fewer potential cost-saving limits on them in Medicare Part D formularies, researchers at John Hopkins University have found.
The results were published Monday in JAMA Internal Medicine. Writing in a research letter, the authors noted that even when generics are available, brands may still receive favorable placement on a formulary, typically through rebates and other price breaks. The cost of drugs in Medicare has been a focus of the Trump administration, which is seeking to halt such rebates in taxpayer-funded plans.
The researchers examined the 57 unique drug formularies offered across all 750 Medicare Part D stand-alone prescription drug plans in 2016 to see how often branded products were given more favorable formulary placement than generic products.
They defined favorable placement as the placement of a branded product in a lower cost-sharing tier or the presence of fewer utilization controls such as prior authorization, step therapy, or quantity limits than its corresponding generic.
The study looked at multisource drugs, meaning drugs for which both versions were available, and examined the lowest strength per drug when multiple strengths were available. Drug prices were compared by dividing the mean cost per unit of the branded products by the mean cost per unit of the corresponding generic drugs in 2016 Medicare Part D claims data.
The 57 formularies covered, on average, 1657 different drugs, of which 935 were multisource. Results showed the following:
The researchers also examined 222 multisource drugs that were covered in all formularies and had branded and generic products covered in at least 1 formulary. Differences were seen here as well:
Drug price often determines beneficiaries’ cost sharing, the authors noted, and favorable formulary placement of branded drugs encourages the use of more expensive products and can lead to higher out-of-pocket costs for Medicare beneficiaries as well as higher expenditures for the Part D program.
Besides enacting the HHS proposal to remove the “safe-harbor” provision that allows drug manufacturer rebates to be paid without triggering the federal anti-kickback statute, another option is to prohibit branded drugs from obtaining favorable placement on Medicare formularies.
However, the authors noted that it is still possible for pharmaceutical makers to restructure payments to drug plans to avoid this restriction.
In their letter, the authors noted that their analysis may have overestimated the difference in price between branded and generic products because of the confidentiality of price concessions.
Reference
Socal MP, Bai G, Anderson GF. Favorable formulary placement of branded drugs in Medicare prescription drug plans when generics are available [published online March 18, 2019]. JAMA Intern Med. doi:10.1001/jamainternmed.2018.7824.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.